HK1036994A1 - Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof - Google Patents

Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof

Info

Publication number
HK1036994A1
HK1036994A1 HK01106685A HK01106685A HK1036994A1 HK 1036994 A1 HK1036994 A1 HK 1036994A1 HK 01106685 A HK01106685 A HK 01106685A HK 01106685 A HK01106685 A HK 01106685A HK 1036994 A1 HK1036994 A1 HK 1036994A1
Authority
HK
Hong Kong
Prior art keywords
mastocytes
degranulation
inhibiting
hybrid protein
basophils
Prior art date
Application number
HK01106685A
Other languages
English (en)
Inventor
Hans Bigalke
Jurgen Frevert
Original Assignee
Biotecon Ges Fur Biotechnologi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Ges Fur Biotechnologi filed Critical Biotecon Ges Fur Biotechnologi
Publication of HK1036994A1 publication Critical patent/HK1036994A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fire-Extinguishing Compositions (AREA)
HK01106685A 1998-05-13 2001-09-21 Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof HK1036994A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19821285 1998-05-13
PCT/EP1999/003272 WO1999058571A2 (de) 1998-05-13 1999-05-12 Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung

Publications (1)

Publication Number Publication Date
HK1036994A1 true HK1036994A1 (en) 2002-01-25

Family

ID=7867540

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106685A HK1036994A1 (en) 1998-05-13 2001-09-21 Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof

Country Status (22)

Country Link
EP (1) EP1084146B1 (cs)
JP (1) JP4549533B2 (cs)
KR (1) KR100580541B1 (cs)
CN (1) CN1241945C (cs)
AT (1) ATE227739T1 (cs)
AU (1) AU755513B2 (cs)
BR (1) BR9910359A (cs)
CA (1) CA2331274C (cs)
CU (1) CU22997A3 (cs)
CZ (1) CZ294376B6 (cs)
DE (1) DE59903410D1 (cs)
DK (1) DK1084146T3 (cs)
ES (1) ES2187200T3 (cs)
HK (1) HK1036994A1 (cs)
HU (1) HUP0103601A3 (cs)
IL (2) IL139478A0 (cs)
MX (1) MXPA00011148A (cs)
NO (1) NO328361B1 (cs)
PL (1) PL201879B1 (cs)
PT (1) PT1084146E (cs)
RU (1) RU2214420C2 (cs)
WO (1) WO1999058571A2 (cs)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
IL153734A0 (en) * 2000-06-28 2003-07-06 Ira Sanders Methods for using tetanus toxin for beneficial purposes in animals (mammals)
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
KR100845278B1 (ko) * 2006-08-04 2008-07-09 포항공과대학교 산학협력단 비만 세포의 활성을 유도하는 펩타이드 및 이를 포함하는면역조절제
EP2719392B1 (en) 2008-06-12 2019-07-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
ES2732205T3 (es) 2008-06-12 2019-11-21 Ipsen Bioinnovation Ltd Proteínas de fusión para uso en el tratamiento del cáncer
CA2731203C (en) * 2008-07-31 2017-01-03 Total S.A. Constructs and methods for the production and secretion of polypeptides
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN102241774B (zh) * 2010-05-27 2014-05-14 四川大学 重组IgE-Fc-抗EGFR单链抗体融合蛋白及其制备方法和用途
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
HUE053935T2 (hu) 2015-01-09 2021-08-30 Ipsen Bioinnovation Ltd Kationos neurotoxinok
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
CA3213914A1 (en) 2021-03-30 2022-10-06 Mikhail KALINICHEV Treatment of pain & inflammatory disorders
CN117396217A (zh) 2021-03-30 2024-01-12 益普生生物制药有限公司 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
PL244930B1 (pl) 2021-12-08 2024-04-02 Gdanski Univ Medyczny Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
PT1084146E (pt) 2003-02-28
IL139478A (en) 2008-06-05
IL139478A0 (en) 2001-11-25
NO328361B1 (no) 2010-02-01
NO20005637L (no) 2000-11-08
JP4549533B2 (ja) 2010-09-22
HUP0103601A3 (en) 2004-06-28
ES2187200T3 (es) 2003-05-16
CN1241945C (zh) 2006-02-15
AU755513B2 (en) 2002-12-12
EP1084146A2 (de) 2001-03-21
CZ294376B6 (cs) 2004-12-15
BR9910359A (pt) 2001-01-09
CA2331274A1 (en) 1999-11-18
CN1300295A (zh) 2001-06-20
WO1999058571A2 (de) 1999-11-18
KR100580541B1 (ko) 2006-05-16
AU4260599A (en) 1999-11-29
HUP0103601A2 (hu) 2002-01-28
CZ20004161A3 (cs) 2001-04-11
DE59903410D1 (de) 2002-12-19
JP2002514659A (ja) 2002-05-21
PL201879B1 (pl) 2009-05-29
EP1084146B1 (de) 2002-11-13
MXPA00011148A (es) 2003-04-22
WO1999058571A3 (de) 2000-02-03
NO20005637D0 (no) 2000-11-08
RU2214420C2 (ru) 2003-10-20
KR20010042825A (ko) 2001-05-25
ATE227739T1 (de) 2002-11-15
PL344752A1 (en) 2001-11-19
DK1084146T3 (da) 2003-02-03
CA2331274C (en) 2010-04-06
CU22997A3 (es) 2004-10-12

Similar Documents

Publication Publication Date Title
HK1036994A1 (en) Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
IL145337A0 (en) Process for partitioning of proteins
ES2145015T3 (es) Proteasas especificas de ubiquitina.
IL228987A0 (en) Purification of proteins using ion exchange chromatography
WO2000023564A3 (en) Protein design automation for protein libraries
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
ATE317441T1 (de) Cathepsin-02-protease
MY113489A (en) Reversible protease inhibitors
TW200510528A (en) Polypeptide inducing apoptosis
DE69832268D1 (en) Peptidyl-2-amino-1hydroxyalkansulfonsäuren als cystein-protease-inhibitoren
CY1110381T1 (el) Πεπτιδια χ-κωνοτοξινης ως αναστολεις των νευρωνικων αμινικων μεταφορεων
GB9318637D0 (en) Enzyme inhibitors
IL145689A0 (en) Methods
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
WO2003087353A3 (en) Purified polypeptides involved in membrane biogenesis
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
DK1002056T3 (da) ppGpp-syntease og ekspressionssystem til forbedret fremstilling af protein af interesse
BG102937A (en) Zona pelucida proteins as contraceptives
ZA200007619B (en) New peptide fragments for protein purification.
WO2003083099A3 (en) Purified polypeptides involved in protein synthesis and modification
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
WO2003087145A3 (en) Purified polypeptides involved in quorum sensing
ES2191785T3 (es) Proteina de accion antitumoral.
WO2003025005A3 (en) Purified bacterial polypeptides involved in protein processing

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100512